Longitudinal Analysis of Bone Density in Human Immunodeficiency Virus-infected Women

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2006 Jun 1

PMID 16735489

Citations 66

Authors

Sara E Dolan

Jenna R Kanter

Steven Grinspoon

Affiliations

Soon will be listed here.

Abstract

Objectives: The objective of the study was to investigate change in bone mineral density (BMD) over time in HIV-infected women in comparison with healthy control subjects similar in age, race, and body mass index (BMI).

Design: This was a prospective cohort study.

Methods: BMD was measured by dual-energy x-ray absorptiometry in 100 HIV-infected females and 100 healthy controls similar in age (41 +/- 1 vs. 41 +/- 1 yr, P = 0.57), BMI (26.1 +/- 0.5 vs. 27.2 +/- 0.4 kg/m(2), P = 0.12), and race (60 vs. 65% non-Caucasian, P = 0.47, HIV-infected vs. controls). Changes in BMD were determined every 6 months over 24 months.

Results: At baseline, HIV-infected subjects had lower BMD at the lumbar spine (1.01 +/- 0.01 vs. 1.07 +/- 0.01 g/cm(2), P = 0.001), hip (0.94 +/- 0.01 vs. 0.98 +/- 0.01 g/cm(2), P = 0.02), and femoral neck (0.83 +/- 0.01 vs. 0.87 +/- 0.01 g/cm(2), P = 0.02). Historical low weight, duration of nucleoside reverse transcriptase inhibitor use, and FSH were significantly associated with lumbar BMD, whereas duration of HIV, BMI, historical low weight, smoking pack-years, N-telopeptide of type 1 collagen, viral load, 25 hydroxyvitamin D, and osteocalcin were associated with hip BMD at baseline. In mixed model longitudinal analyses, BMD remained lower in HIV-infected subjects than in controls over 24 months of follow-up (P = 0.001 for the spine, P = 0.04 for the hip, and P = 0.02 for the femoral neck). These differences remained significant controlling for age, race, BMI, and menstrual function. In contrast, rates of change for the spine (P = 0.79), hip (P = 0.44), and femoral neck (P = 0.34) were not different between the HIV and control groups over 2 yr. In the HIV group, longitudinal changes in BMD were not associated with current protease inhibitor, nucleoside reverse transcriptase inhibitor, or non-nucleoside reverse transcriptase inhibitor use but were associated with CD4 count, weight, FSH, N-telopeptide of type 1 collagen, and baseline BMD.

Conclusions: BMD is reduced at the spine, hip, and femoral neck among women with HIV in relationship to low weight, duration of HIV, smoking, and increased bone turnover. Over 2 yr of follow-up, BMD remained stable but lower in HIV-infected women, compared with control subjects.

Citing Articles

Optimizing bone health in people living with HIV: insights from a network meta-analysis of randomized controlled trials.

Wang J, Chung S, Wu P, Tu Y, Lai P, Tai T EClinicalMedicine. 2025; 81:103103.

PMID: 40040862 PMC: 11876934. DOI: 10.1016/j.eclinm.2025.103103.

Contribution of viral and bacterial infections to senescence and immunosenescence.

Reyes A, Ortiz G, Duarte L, Fernandez C, Hernandez-Armengol R, Palacios P Front Cell Infect Microbiol. 2023; 13:1229098.

PMID: 37753486 PMC: 10518457. DOI: 10.3389/fcimb.2023.1229098.

Long-Term Change in Bone Mineral Density in Women Living With HIV: A 10-Year Prospective Controlled Cohort Study.

Macdonald H, Maan E, Berger C, Cote H, Murray M, Pick N JBMR Plus. 2023; 7(8):e10761.

PMID: 37614300 PMC: 10443077. DOI: 10.1002/jbm4.10761.

Bone mineral density among virologically suppressed Asians older than 50 years old living with and without HIV: A cross-sectional study.

Wattanachanya L, Sunthornyothin S, Apornpong T, Lwin H, Kerr S, Gatechompol S PLoS One. 2022; 17(11):e0277231.

PMID: 36409740 PMC: 9678298. DOI: 10.1371/journal.pone.0277231.

The effect of anti-retroviral therapy on fracture healing : an in vivo animal model.

Graham S, Jalal M, Lalloo D, Simpson A Bone Joint Res. 2022; 11(8):585-593.

PMID: 35942801 PMC: 9396923. DOI: 10.1302/2046-3758.118.BJR-2021-0523.R2.

References

Bruera D, Luna N, David D, Bergoglio L, Zamudio J . Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003; 17(13):1917-23. DOI: 10.1097/00002030-200309050-00010. View

Fernandez-Rivera J, Garcia R, Lozano F, Macias J, Garcia-Garcia J, Mira J . Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials. 2003; 4(5):337-46. DOI: 10.1310/4X0H-UVMJ-BHYW-CPFB. View

Brown T, Ruppe M, Kassner R, Kumar P, Kehoe T, Dobs A . Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004; 89(3):1200-6. DOI: 10.1210/jc.2003-031506. View

Dolan S, Huang J, Killilea K, Sullivan M, Aliabadi N, Grinspoon S . Reduced bone density in HIV-infected women. AIDS. 2004; 18(3):475-83. DOI: 10.1097/00002030-200402200-00014. View

Madeddu G, Spanu A, Solinas P, Calia G, Lovigu C, Chessa F . Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004; 48(1):39-48. View

Tebas P, Powderly W, Claxton S, Marin D, Tantisiriwat W, Teitelbaum S . Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000; 14(4):F63-7. PMC: 3170993. DOI: 10.1097/00002030-200003100-00005. View

Teichmann J, Stephan E, Discher T, Lange U, Federlin K, Stracke H . Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection. Metabolism. 2000; 49(9):1134-9. DOI: 10.1053/meta.2000.8609. View

Carr A, Miller J, Eisman J, Cooper D . Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001; 15(6):703-9. DOI: 10.1097/00002030-200104130-00005. View

Knobel H, Guelar A, Vallecillo G, Nogues X, Diez A . Osteopenia in HIV-infected patients: is it the disease or is it the treatment?. AIDS. 2001; 15(6):807-8. DOI: 10.1097/00002030-200104130-00022. View

10.

Nolan D, Upton R, McKinnon E, John M, James I, Adler B . Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001; 15(10):1275-80. DOI: 10.1097/00002030-200107060-00009. View

11.

Mondy K, Powderly W, Claxton S, Yarasheski K, Royal M, Stoneman J . Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005; 38(4):426-31. DOI: 10.1097/01.qai.0000145352.04440.1e. View

12.

Yin M, Dobkin J, Brudney K, Becker C, Zadel J, Manandhar M . Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int. 2005; 16(11):1345-52. PMC: 3108020. DOI: 10.1007/s00198-005-1845-0. View

13.

Aukrust P, Haug C, Ueland T, Lien E, Muller F, Espevik T . Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999; 84(1):145-50. DOI: 10.1210/jcem.84.1.5417. View

14.

Carr A, Samaras K, Chisholm D, Cooper D . Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998; 351(9119):1881-3. DOI: 10.1016/S0140-6736(98)03391-1. View

15.

Paton N, Macallan D, Griffin G, Pazianas M . Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int. 1997; 61(1):30-2. DOI: 10.1007/s002239900288. View

16.

Genant H, Engelke K, Fuerst T, Gluer C, Grampp S, Harris S . Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res. 1996; 11(6):707-30. DOI: 10.1002/jbmr.5650110602. View

17.

Kanis J . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994; 4(6):368-81. DOI: 10.1007/BF01622200. View

18.

Finkelstein J, Cleary R, Butler J, Antonelli R, Mitlak B, Deraska D . A comparison of lateral versus anterior-posterior spine dual energy x-ray absorptiometry for the diagnosis of osteopenia. J Clin Endocrinol Metab. 1994; 78(3):724-30. DOI: 10.1210/jcem.78.3.8126149. View

19.

Mazess R, Barden H, Bisek J, Hanson J . Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr. 1990; 51(6):1106-12. DOI: 10.1093/ajcn/51.6.1106. View

20.

Cozzolino M, Vidal M, Arcidiacono M, Tebas P, Yarasheski K, Dusso A . HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003; 17(4):513-20. DOI: 10.1097/00002030-200303070-00006. View